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ABSTRACT
Objective: Psychological distress is common in
patients with cancer. We need a rapid means of
screening for and identifying depression and anxiety in
patients with cancer. The present study evaluates the
potential of the Eastern Cooperative Oncology
Group (ECOG) performance status (PS) scoring as a brief
screening tool to assess psychological distress in routine
cancer care. The ECOG PS is widely used by oncologists
and the WHO, as a standardised measure to assess
general well-being in patients with cancer and quality of
life in cancer trials. We examine the discrepancy between
patient-rated and oncologist-rated PS scores on the
ECOG in a comparative assessment against the Hospital
Anxiety and Depression Scale (HADS).
Methods and design: This is a prospective evaluation
of approximately 500 ambulatory adult cancer patients
from a large academic medical centre. Participants will be
asked to assess their own ECOG PS on a scale of 0–4,
which will be compared to ECOG PS as rated by their
oncologists. Higher ECOG PS scores indicate poorer daily
functioning. Both patient-rated and oncologist-rated
ECOG PS and their absolute differences will be tested for
predictive and concurrent validity against the HADS. A
HADS cut-off ≥15 will be used. Ethics approval for this
study has been secured from the institutional ethics
board. Outcomes are re-evaluated at 4-week to 6-week
and 1-year follow-up.
Conclusion: This study holds practical significance for
rapid screening of psychological distress in the cancer
clinic with the use of the ECOG PS scoring. Given the
high prevalence of anxiety and depression in patients
with cancer, screening is important to increase its
recognition, which will, in turn, help to direct referrals
and deliver appropriate intervention. This study also
generates greater insight into the association between
psychosomatic complaints and psychological distress.
Trial registration number: MEC 896.52.
INTRODUCTION
We need a rapid means of screening for
and identifying depression and anxiety in
patients with cancer. While having patients
undergoing psychological assessment inter-
views or complete standardised anxiety and
depression questionnaires is ideal, cancer
ARTICLE SUMMARY
Article focus
▪ We need a rapid means of screening for and
identifying depression and anxiety in patients
with cancer given its high prevalence and associ-
ation with poorer long-term outcomes.
▪ We propose the use of the Eastern Cooperative
Oncology Group (ECOG) Performance status
(PS) scoring as a brief screening instrument for
psychological distress in patients with cancer. It
is hypothesised that discrepancy between
patient-rated and oncologist-rated performance
status scores at baseline and follow-up are asso-
ciated with higher levels of psychological dis-
tress and poorer clinical outcomes in patients
with cancer.
Key messages
▪ This study holds practical significance for rapid
screening of psychological distress in the cancer
clinic with the use of the ECOG performance status
scoring.
▪ Although the ECOG was not developed specific-
ally to detect depression or anxiety, it has good
potential to assist in the recognition of distress.
▪ Implementation of the ECOG as part of routine sys-
tematic screening for psychological distress
appears feasible because of its distinct advantage
of fundamental use in PS scoring in oncology.
Strengths and limitations of this study
▪ This is the first study to examine discrepancy in
ECOG PS as a predictor of anxiety and depression
in cancer patients using a prospective design.
▪ Further study is needed to determine if the rela-
tionship between PS and anxiety and depression
is predictive, prognostic, causal or merely
associative.
▪ Further validation using criterion-standard struc-
tured clinical interviews is still required.
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Open Access Protocolclinics are busy places where oncologists and staff nurses
are often overworked.
1 Oncologists are often not sufﬁ-
ciently trained in psychological assessment or testing,
nor do they have the time to do so.
2 Several studies have
shown that oncologists are not especially skilled in either
discussing psychological problems in general,
3 or at
recognising anxiety and depression.
24Published data
suggest that the ability of doctors to accurately detect
psychiatric morbidity in patients is often little better
than that of chance.
2
As a result psychological distress may go undetected
and when recognised, it is more likely to run a more
severe and unremitting course, and in some cases to be
clearly impacting patients’ lives and even cancer treat-
ment in some way. Although tremendous attention has
been given to the early detection and treatment of
cancer, the issue of psychological distress has lagged
behind. There is little consensus with regard to even the
criterion and management of anxiety and depression
associated with cancer. Early detection is as crucial in
the matter of treatment and prognosis in cancer as in
anxiety and depression, with greater psychological dis-
tress linked to poorer health outcomes.
5
We lack adequate screening instruments measuring
psychological distress in oncology settings.
6 For a screen-
ing or monitoring tool to be accepted in routine prac-
tice, it needs to be brief, relevant in its utility and simple
enough to interpret while retaining the necessary speci-
ﬁcity and sensitivity.
5 What we need is to capitalise on an
existing tool as a brief form of assessment that can func-
tion as a surrogate tool for screening depression and
anxiety.
7 The Eastern Cooperative Oncology Group
(ECOG) performance status (PS) is one such measure.
As a standardised measure of PS in routine oncology
practice, the ECOG bears the potential for widespread
usage to screen for psychological distress in this setting
due to its high acceptability and ease of use.
PS is one of the most widely accepted patient evalua-
tions used in clinical practice and oncology trials. It is
typically assessed for all types of cancer due to its
demonstrated efﬁcacy in the measurement of treatment
responses, survival length, prognostic value as well as a
criterion for suitability for chemotherapy and clinical
trials.
8 Yet rarely, if ever, are PS scores compared across
different cancer types. Most commonly reported as part
of a randomised clinical trial, the majority of cancer
studies or trials where PS also measured present data
where sample sizes are generally inadequate or moder-
ate at the best.
9 The average cancer trial size wherein PS
is most frequently measured is 200, or an average of 175
for randomised clinical trials.
10
Oncologists have generally found the ECOG easy to
use in daily clinic practice.
781 1Although traditionally
scored by the oncologist, several studies have arrived at
rather interesting results when comparing PS scores as
rated by the patients to those rated by their oncologists.
7
Prior studies in this area already show that there is
a signiﬁcant difference between patient-rated and
oncologist-rated PS,
12 with depression being a confoun-
der where it comes to functional status.
3 These previous
studies examining discrepancy between patient-rated
and oncologist-rated ECOG, however, are also restricted
to patients with cancer in a single site, with most of such
studies focusing primarily on non-small cell lung
cancer.
71 1 –13 Findings from these studies may not be
representative of psychological distress in patients with
other types of cancer. It would therefore be interesting
to extend this study to include patients with other
cancer types.
11
The main goal of this proposed study is to examine the
feasibility of the ECOG PS as a psychological distress
screening instrument. We intent to test the predictive and
concurrent validity of the ECOG PS against the Hospital
Anxiety and Depression Scale (HADS). The present
study is the ﬁrst to prospectively investigate the use of dis-
crepancy between patient-rated and oncologist-rated
ECOG PS to gauge psychological distress in patients with
cancer.
RESEARCH QUESTIONS
1. To what extent do patient-rated versus oncologist-rated
ECOG PS agree? If discrepant, what is their under-
lying cause?
2. To what degree does the ECOG assess psychological
distress? Does discrepancy in PS predict psychological
distress at baseline and subsequent 4-week to 6-week
and 1-year follow-up?
HYPOTHESIS
It is hypothesised that poorer or discrepant PS scores
are associated with higher levels of psychological distress,
rather than the level of activity. It is also posited that dis-
crepancy between patient-rated ECOG at baseline and
follow-up is also associated with an increased likelihood
of comorbid anxiety or depression in patients with
cancer.
METHODS/DESIGN
This is a prospective single-centre study, in the context
of patients about to see their oncologist for a consult-
ation in an academic medical centre. Patients will be
asked to assess their own ECOG PS score on a scale
between 0 and 4. We then compare these to ECOG
scores rated by their oncologists (extracted from their
medical records). The absolute discrepancy in scores
will then subsequently be analysed against patient HADS
scores.
We will attempt to enrol approximately 500 consecutive
patients who have been referred to the adult clinical
oncology unit with a diagnosis of cancer from November
2011 to August 2012. Patients should be receiving or plan
to receive at least one form of treatment (i.e, chemother-
apy or radiotherapy) at any point in their disease trajec-
tory. Patients aged less than 18 years are excluded, as are
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speciﬁcally the inability to understand the instrument
language in English or comprehend interviews con-
ducted in all major spoken languages: English, Chinese
or the Malay language. We chose not to apply additional
exclusion criteria that would limit the applicability of
ﬁndings to the general patient with cancer population
unnecessarily.
Study variables
A data extraction form that has been speciﬁcally devel-
oped will be used to obtain relevant demographic and
clinical data from patient records. The speciﬁc variables
and selected outcome variables of interest include age,
sex, race, marital status, education and employment
status. Relevant clinical information examined includes
the primary cancer site and tumour stage. Other vari-
ables that will be looked at include treatment planned
or received such as surgery, chemotherapy and/or
radiotherapy.
Research tools
The questionnaires used in this study include the ECOG
PS as rated by patients themselves and by their oncolo-
gists, as well as the HADS scale. All questionnaires used
have obtained permission for use from the respective
authors and will be cited.
The ECOG PS is highly valid and is one of the most
widely used instruments in clinical cancer practice and
research.
781 1In this study, the single-item score will be
rated by both patients and their oncologists on a scale of
0–4 (worse scores denoting poorer PS and higher levels
of psychological distress). The ECOG PS score of 5 (indi-
cating death) will not be used in the patient version of
the scale. Refer to appendix 1 for a copy of the ECOG.
The HADS, a 14-item instrument has also been well-
validated and will be employed for use in the detection
of anxiety and depression among cancer patients.
Overall scores range from 0 to 42, with higher scores
indicating greater distress. A cut-off point of greater
than or equal to 15 will be used. Preliminary testing with
18 patients (male-to-female ratio=1:1) conducted in
October 2011 for the HADS yielded an α of 0.91.
Sample size estimation
Using an online sample size calculator (Raosoft),
14 we
adopted a 0.05% margin of error which required a total of
306 participants to accurately (95% CI) represent a vari-
able with 50% response distribution in a population of
approximately 1500 patients with cancer seen annually.
Although an estimated ﬁgure of 306 patients would be suf-
ﬁcient to test our hypothesis in a cross-sectional design, a
ﬁnal sample size of 500 was chosen to balance attrition at
various follow-up points (estimated at 20–40%) and to
facilitate regression analyses. Pilot testing computed an
r=0.75, which, following Cohen’s conventions, can be
interpreted as a large effect size. A priori power calculation
using an observed effect size of 0.75 with the conventional
probability level of 0.05 in a sample size of 306 would
result in an observed power of 0.99 (two-tailed).
Procedure
Patients will be directly approached in the waiting room
of the adult oncology unit while waiting to see their
oncologist. Participants will ﬁrst be given verbal informa-
tion on the goal of the study and screened to check
whether they meet all inclusion and exclusion criteria.
Upon assent to participate, informed consent will be
obtained and an additional information leaﬂet be given.
Participants will be asked to circle the number that best
describes the overall distress that they experienced over
the previous week for both the ECOG and HADS.
Face-to-face interviews will be conducted in all major
languages (English, Bahasa Malaysia and Chinese). The
follow-up time ranges from 4 to 6 weeks and 1 year, at
which the assessments will be repeated via face-to-face
interview, or via telephone interview if necessary.
Questionnaire administration
The use of a questionnaire design makes this study cost-
efﬁcient and allows for rapid yet effective screening of psy-
chological distress in our population. Oncologist-assessed
ECOG PS scores will be extracted from patient oncology
records.
ANALYSIS OF DATA
The mean and SDs for anxiety and depression for each
cancer type will be determined. All data will be coded
based on the instructional guidelines as contained in
the questionnaire scoring manuals. Responses to the
HADS will be analysed according to published recom-
mendations.
15 Two-sided tests will be used, while
p values of ≤0.05 will be regarded as statistically signiﬁ-
cant. For all analyses, a two-sided p value≤0.05 will be
applied. All analyses will be performed using the
Statistical Package for Social Sciences (SPSS) V.20.
Comparison of mean scores
Comparison of baseline scores, change in scores
between and within groups, as well as identiﬁcation of
subjects with improved, stable and worsened scores over
time will be performed using a t test, Mann-Whitney test,
analysis of variance (ANOVA) or, alternately, a non-
parametric approach such as Kruskal-Wallis as deemed
appropriate. Proportions will be compared using χ
2 test
or Fisher’s exact test.
Comparison between ECOG and HADS scores
Comparison between the good (0–1), intermediate (2)
and poor (3–4) PS patient groups will be made using
one-way ANOVA. Pearson correlation coefﬁcient (r) will
be used to express the relationship between the psycho-
logical distress as measured using the HADS and PS
using the ECOG. Differences in the two subscales of the
HADS as well as mean ECOG scores will also be
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overall levels of psychological distress and PS will be
measured using Spearman’s correlation coefﬁcient.
Kendall’st a u( τ)c o e f ﬁcient will be used to measure the
portion of ranks that match between patient-rated and
oncologist-rated PS. Additionally, a paired t test, or the
non-parametric Kolmogorov-Smirnov test (KS-test) may be
used to determine whether there is a signiﬁcant difference
between the patient-rated versus oncologist-rated dataset.
Descriptive statistics
Descriptive statistical analysis will be performed for all
variables. Continuous variables will be reported using
means and SDs or median and IQR. For dichotomous
variables, absolute numbers and percentages will be pre-
sented. Differences between concordant and discrepant
PS groups in demographic characteristics, clinical vari-
ables, anxiety, depression and PS will be assessed using t
test or Mann-Whitney tests for continuous variables, and
the χ
2 statistic or Fisher’s exact test for categorical vari-
ables. Linear regression, logistic regression or the
Wilcoxon-Mann-Whitney rank sum test will be used as
appropriate to assess the impact of demographic and
clinical variables on group differences in depression,
anxiety and PS. Variables included in subsequent ana-
lyses include those that demonstrate statistically signiﬁ-
cant differences between the study groups in univariate
analyses.
Imputation of missing values
All responses with more than 5% missing values will ﬁrst
be removed from the data set. For the remaining items,
missing values will be replaced by an imputation process
based on an expectation–maximisation algorithm using
NORM software. This imputation ensures that should
subsequent exploratory factor analysis be done, which
processes a large number of items, the data set is not
reduced too greatly. In order to assess the inﬂuence of
imputation on the psychometric results, all analyses will
additionally be carried out with non-imputed values
after the factor analysis. Should differences arise, ﬁnd-
ings from both imputed and non-imputed data will be
presented to allow for comparison. Careful note will be
made for all missing data on individual items. Missing
data, however, remains a serious issue for quality of life
studies.
15 16
DISCUSSION
This is the ﬁrst study to longitudinally examine the use
of discrepancy in ECOG as a predictor of anxiety and
depression in cancer patients in a comparative assess-
ment over time. We propose the use of the ECOG as a
brief screening instrument for depression and anxiety in
cancer patients and hypothesise that poorer or more dis-
crepant patient-rated ECOG scores may be an indicator
of greater psychological distress. Given the high preva-
lence of anxiety and depression in cancer, screening is
critical in increasing case recognition to deliver appro-
priate interventions and prioritise referrals.
While the ECOG was originally developed as a
measure of PS, its brevity and simplicity makes it feasible
for widespread adoption as a surrogate tool to detect
anxiety and depression. Most oncologists lack familiarity
with psychiatric nosology.
1 Screening for anxiety and
depression using the ECOG PS scale does not require
special training because PS is routinely assessed by
oncologists across all cancer types.
There is an emerging trend towards simplifying the
assessment of depression and anxiety in outpatient
cancer settings,
17 particularly as treatment and care has
shifted to ambulatory settings. Shorter than any other
standard assessment such as the HADS and Beck
Depression Inventory, the ECOG functions much like
the single-item Distress Thermometer. We predict that
the acceptability of the ECOG as a measure would likely
be higher and less likely to burden the clinic in terms of
time and cost compared to any other form of
assessment.
Patients have been shown able to accurately assess
their own PS.
13 The single-item ECOG PS is also easy for
patients to rate, especially with the emergence of differ-
ent versions of the PS scale in visual analogue format
13
suitable for paediatric or illiterate cancer populations, or
simply where communication issues might arise from a
language barrier.
While data which come directly from those experiencing
the cancer afford an insightful perspective, there is greater
practical value in using the ECOG to comparatively
measure discrepancy in PS scores, rather than solely
relying on either patient-rated or oncologist-rated scores.
Discrepancy on the ECOG is also easy to eyeball, while
scores can be quickly compare over time when reviewed at
each visit.
This study carries several important implications for
oncology clinic practice, in that discrepancy in ECOG
scores, or patient-rated ECOG can be used as a patient-
reported outcome measure to raise, discuss as well as rou-
tinely monitor psychological concerns.
11 Asking patients
to score their own ECOG opens up avenues for discussion
of psychological concerns and reduces the likelihood of
measurement, cultural and educational bias.
Special attention should be given to cancer patients
who demonstrate poorer self-rated PS. As suggested by
Ando,
12 patients who rate themselves signiﬁcantly higher
on ECOG scores compared with assessment by their
oncologist may actually be presenting a subconscious bid
for care and reassurance towards their oncologists. This
is consistent with the local cultural inﬂuence which is
not dissimilar to those of other Asian cultures where
emotions are suppressed.
18
Owing to indeﬁnite symptomatology such as fatigue,
lack of appetite and weight loss,
19 differentiating symp-
toms caused by cancer and its treatment from standard
criteria-based syndromes of major depression and clin-
ical grade anxiety is not easy.
20 The use of the ECOG
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does not exclude psychosomatic distress. Multiple socio-
cultural barriers are inherent in seeking medical and
psychosocial information, treatment and care.
18
Regardless of physical disease,
17 it is not uncommon for
mood disorders to be expressed as somatic rather than psy-
chological symptoms across a number of cultures, partly to
avoid the perceived stigma of a psychiatric disorder.
1
Patients from Asian cultures tend to focus on somatising
and physiologic symptomatology rather than mental symp-
toms
18 21 and to be culturally constrained where it comes
to reporting emotional states such as depression.
21
Physicians too are often reluctant to probe into psy-
chological concerns.
2 This may be, in part, due to the
biomedical training and orientation of oncologists, who
may prove wary of forming attachment to patients, which
is also a barrier to supportive care. A rigid biomedical
agenda also means oncologists are more comfortable
treating somatic symptoms such as pain, nausea and dys-
pnoea. It is likely that physicians who are trained locally
would be even less comfortable addressing distress due
to cultural constraints. This gives rise to the question of
how likely oncologists are to refer patients for further
psychological or psychiatric assessment. Previous studies
report the consultation rate from oncologists to
consultation-liaison psychiatrists to be only 4–10%
among cancer patients.
52 2
The majority of cancer patients with (clinically signiﬁ-
cant) anxiety and depression do not see mental health
professionals but do see their oncologists. However, rela-
tively few oncologists have sufﬁcient knowledge and
expertise to assess and treat psychological distress.
3 Prior
research in this context shows that oncologists are often
unable to detect depression and anxiety, often stemming
from a lack conﬁdence in assessing distress and using
psychometric instruments.
23
By no means, however, should assessment of psycho-
logical distress using the ECOG replace comprehensive
psychiatric evaluation.
5 Systematic screening using the
ECOG can nonetheless increase case recognition and
allow for referral of distressed patients for consultation-
liaison or ideally psycho-oncology services.
251 9Further
study is needed to determine whether the relationship
between PS and anxiety and depression is predictive,
prognostic, causal or merely associative.
IMPLICATIONS
Although the ECOG was not developed speciﬁcally to
detect depression or anxiety, it has good potential to
assist in the recognition of distress. Findings from this
study would help to validate the surrogate function of an
existing clinic tool. Implementation of the ECOG as part
of routine systematic screening for psychological distress
appears feasible because of its distinct advantage of fun-
damental use in PS scoring in oncology, although
further validation using criterion-standard structured
clinical interviews is still required.
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APPENDIX 1
Table A1 ECOG performance status score
ECOG Score
Fully active, able to carry on all predisease
performance without restriction
0
Restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or
sedentary nature, eg, light house work and office
work
1
Ambulatory and capable of all self-care but unable
to carry out any work activities. Up and about more
than 50% of waking hours
2
Capable of only limited self-care, confined to bed
or chair more than 50% of waking hours
3
Completely disabled. Cannot carry on any
self-care. Totally confined to bed or chair
4
Source:O k e net al
8.
ECOG, Eastern Cooperative Oncology Group
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